Identification of genes differentially expressed in melanoma sublines derived from a single surgical specimen characterised by different sensitivity to cytotoxic T-lymphocyte activity

Schweizerische Medizinische Wochenschrift

Volumn 130, Issue 17, 2000, Pages 617-624

  Kocher, Th ^a,b   Schraml, P ^a   Spagnoli, G C ^a   Harder, F ^a   Heberer, M ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b ZLF   (Switzerland)

Author keywords

Differential display; Melanoma; Tumour specific immune response

Indexed keywords

GLUTAMATE AMMONIA LIGASE; MESSENGER RNA; MITOCHONDRIAL RNA; RIBOSOME PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA3; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DNA SEQUENCE; EXPRESSED SEQUENCE TAG; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MELANOMA; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; TUMOR ESCAPE;

BASE SEQUENCE; CYTOTOXICITY, IMMUNOLOGIC; DNA PROBES; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0034728823     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kageshita T, Wang Z, Calorini L, Yoshii A, Kimura T, Ono T, et al. Selective loss of human leukocyte class I specificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 1993;53:3349-54.
2. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulè JJ, Rosenberg SA, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
3. Boon T, Cerottini JC, van den Eynde B, van der Bruggen P, van Pel A. Tumor antigens rccognized by T-lymphocytes. Ann Rev Immunol 1994;12:337-65.
4. Liang P, Pardee AB. Differential display of eukaryotic mRNA by means of the polymerase chain reaction. Science 1992; 257:967-71.
5. Lüscher U, Filgueira L, Juretic A, Zuber M, Lüscher NJ, Heberer M, et al. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible energy of tumor infiltrating lymphocytes, Int J Cancer 1994;57:612-9.
6. Filgueira L, Zuber M, Juretic A, Lüscher U, Caetano V, Harder F, et al. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes. Cell Immunol 1993;150:205-18.
7. Juretic A, Jürgens-Göbel J, Schaefer C, Noppen C, Willimann TE, Kocher T, et al. Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage. Int J Cancer 1996;68:471-8.
8. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
9. Jäger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jäger D, et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67:54-62.
10. Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, et al. Tumor regression observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
11. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6: 199-208.
12. Noppen C, Schaefer C, Zajac P, Schütz A, Kocher T, Kloth J, et al. C-type lectin-like receptors in peptide-specific HLA class-I restricted cytotoxic T-lymphocytes: differential expression and modulation of effector functions in clones sharing identical TCR structure and epitope specificity. Eur J Immunol 1998;28:1134-42.
13. Walker PR, Saas P, Dietrich PY. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol 1998;10:564-72.
14. Collins CL, Wasa M, Souba WW, Abcouwer SF. Regulation of glutamine synthetase in human breast carcinoma cells and experimental tumors. Surgery 1997;122:451-64.
15. Schraml P, Shipman R, Colombi M, Ludwig CU. Identification of genes differentially expressed in normal lung and non-small cell lung carcinoma tissue. Cancer Res 1994; 54:5236-40.
16. Epstein SP, Baer RL, Thorbecke GJ, Belsito DV. Immunosuppressive effects of transforming growth factor beta: inhibition of the induction of Ia antigen on Langerhans cells by cytokines and of the contact hypersensitivity response. J Invest Dermatol 1991;96:832-7.
17. Galili N, Davis RJ, Fredericks WJ, Mukhopadhayay S, Rauscher FJ, Emanuel BS, et al. Fusion of a forkhead domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;5:230-5.
18. Barr FG. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomyosarcoma. Cancer Res 1999;59:1711-5.